Cyclooxygenases inhibitors and other compounds with antiinflamatory potential in osteoarthrosis - Part II;Inhibitory cyklooksygenaz i inne zwia̧zki o potencjale przeciwzapalnym w chorobie zwyrodnieniowej stawów (osteoartrozie - OA) - czȩść II

Polski Merkuriusz Lekarski

Volumn 30, Issue 175, 2011, Pages 82-86

  Dzielska Olczak, MaŁgorzata ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

H2S Releasing cyclooxygenases inhibitors; Hydrogen sulfide (H2S); Lipoxins; Nitric oxide (NO); NO NSAIDs; Osteoarthrosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; DRUG DERIVATIVE; NAPROXEN; NAPROXEN N BUTYL NITRATE; NAPROXEN-N-BUTYL NITRATE; NITRIC OXIDE DONOR; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL; DRUG INTERACTION; HUMAN; OSTEOARTHRITIS; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ASPIRIN; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; HUMANS; NAPROXEN; NITRIC OXIDE DONORS; OSTEOARTHRITIS;

EID: 79952145875     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Abramson S.B.: Nitric oxide in inflammation and pain associated with osteoarthritis. Arthritis Res. Ther., 2008, 10 (supl. 2), S2.
2. Baerwald C., Verdecchia P., Duquesroix B. i wsp.: Efficacy, safety and effects on BP of Naproxcinod 750 Mg bid compared with Placebo and Naproxen 500 Mg bid in patients with osteoarthritis of the hip. Arthritis Rheum., 2010, 18 [Epub ahead of print].
3. Brzozowski T., Konturek P.C., Pajdo R. i wsp.: Physiological mediators in nonsteroidal anti-inflammatory drugs (NSAIDs)-induced impairment of gastric mucosal defense and adaptation. Focus on nitric oxide and lipoxins. J. Physiol. Pharmacol., 2008, 59, supl. 2, 89-102.
4. Fiorucci S., Di Lorenzo A., Renga B. i wsp.: Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic acid 4-(nitrooxy)butyl ester]) interactions with aspirin ingastric mucosa of arthritic rats reveal a role for aspirin triggered lipoxin, prostaglandins, and NO in gastric protection. J. Pharmacol. Exp Ther., 2004, 311, 1264-1271.
5. Fiorucci S., Distrutti E.: Cyclo-oxygenase (COX) inhibiting nitric oxide donating (CINODs) drugs: a review of their current status. Curr. Top. Med. Chem., 2007, 7, 277-282.
6. Geusens P.: Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donátor (CINOD). Expert Opin. Biol. Ther., 2009, 9, 649-657.
7. Hawkey C.J., Jones J.I., Atherton CT. i wsp.: Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator proof of concept study in humans. Gut 2003, 52, 1537-1542.
8. Hill M.C., Sindet-Pederson S., Seymour R.A. i wsp.: Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies. Clin. Ther., 2006, 28, 1279-1295.
9. Karlsson J., Pivodic A., Aguirre D. i wsp.: TJ. Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donátor naproxcinod in treating osteoarthritis of the hip or knee. J. Rheumatol., 2009, 36(6), 1290-1297.
10. Lohmander L.S., McKeith D., Svensson O. i wsp.: A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann. Rheum. Dis., 2005, 64(3), 449-456.
11. Mackenzie I.S., Rutherford D., MacDonald T.M.: Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. Arthritis Res. Ther., 2008, 10, supl. 2, S3.
12. Maderna P., Godson C.: Lipoxins: resolutionary road. Br. J. Pharmacol., 2009, 158 (4), 947-959.
13. Muscará M.N., Wallace J.L.: COX-inhibiting nitric oxide donors (CINODs): potential benefits on cardiovascular and renal function. Cardiovasc. Hematol. Agents Med. Chem., 2006, 4 (2), 155-164.
14. Nowak J.Z.: Przeciwzapalne "prowygaszeniowe" pochodne wielonienasyconych kwasów tluszczowych omega 3 i omega 6. Postȩpy Hig. Med. Dośw., 2010, 64, 115-132.
15. Perini R., Fiorucci S., Wallace J.L.: Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors. Can. J. Gastroenterol., 2004, 18 (4), 229-236.
16. Schnitzer T.J., Kivitz A., Frayssinet H. i wsp.: Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, mutticenter study. Osteoarthritis Cartilage, 2010, 18, 629-639.
17. Schnitzer T.J., Kivitz A.J., Lipetz R.S. i wsp.: Comparison of the COXinhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee. Arthritis Rheum., 2005, 53 (6), 827-837.
18. Wallace J.L.: Hydrogen sulfide-releasing anti-inflammatory drugs. Trends Pharmacol. Sci., 2007, 28 (10), 501-505.
19. Wallace J.L.: Physiological and pathophysiological roles of hydrogen sulfide in the gastrointestinal tract. Antioxidants & Redox Signaling, 2010, 12, 1125-1133.
20. Wallace J.L., Caliendo G., Santagada V. i wsp.: Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology, 2007, 132 (1), 261-271.
21. Wallace J.L., Caliendo G., Santagada V. i wsp.: Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br. J. Pharmacol., 2010, 159, 1236-1246.
22. Wallace J.L., Miller M.J.S.: Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology, 2000, 119, 512-20.
23. Walley M., Sigthorsson G., Hotz-Behofsits C. i wsp.: The effects of AZD3582 [4-(nitroxy)butyl-(2S)-2-(6-methoxy-2-naphthyl) propanoate], and naproxen on key pathogenic steps in NSAID-enteropathy in the rat. Inflammopharmacology, 2007, 15 (3), 119-123.
24. White W.B., Schnitzer T.J., Fleming R. i wsp.: Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. Am. J. Cardiol., 2009, 104 (6), 840-845.
25. Whittle B.J.: Nitric oxide and the gut injury induced by non-steroidal antiinflammatory drugs. Inflammopharmacology, 2003, 11 (4), 415-422.
26. Wilder-Smith C.H., Jonzon B., Fornstedt-Wallin B. i wsp.: Dose-effect comparisons of the CINOD AZD3582 and naproxen on upper gastrointestinal tract mucosal injury in healthy subjects. Scand. J. Gastroenterol., 2006, 41 (3), 264-273.